STARGARDT'S MACULAR DYSTROPHY

Clinical trials for STARGARDT'S MACULAR DYSTROPHY explained in plain language.

Never miss a new study

Get alerted when new STARGARDT'S MACULAR DYSTROPHY trials appear

Sign up with your email to follow new studies for STARGARDT'S MACULAR DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Experimental eye injection aims to halt rare genetic vision loss

Disease control Completed

This completed Phase 2 trial tested whether regular injections of an experimental drug called Zimura into the eye could safely slow the progression of vision loss in people with a rare genetic eye disease called Stargardt's. The study involved 121 participants who received either…

Matched conditions: STARGARDT'S MACULAR DYSTROPHY

Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:10 UTC

STARGARDT'S MACULAR DYSTROPHY

Get alerted when new STARGARDT'S MACULAR DYSTROPHY trials appear

Experimental eye injection aims to halt rare genetic vision loss